Induction of sensitivity to NK-mediated cytotoxicity by TNF-α treatment: Possible role of ICAM-3 and CD44

Leukemia

Volumn 12, Issue 10, 1998, Pages 1565-1572

  Maki, G ^a   Krystal, G ^a   Dougherty, F ^a   Takei, F ^a   Klingemann, H G ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Leukemia; NK resistance; TNF

Indexed keywords

GAMMA INTERFERON; HERMES ANTIGEN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; INTERCELLULAR ADHESION MOLECULE 3; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NATURAL KILLER CELL; PRIORITY JOURNAL; TARGET CELL;

EID: 0031654614     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401145     Document Type: Article

References (13)

1. Beran M, Hansson M, Kiessling R. Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells. Blood 1996; 61: 596-599.
2. Attal M, Blaise D, Marit G, Payen C, Michallet M, Vernant JP, Sauvage C, Troussard X, Nedellec G, Pico J, Huguet F, Stoppa AM, Broustet A, Sotto JJ, Pris J, Maraninchi D, Reiffers JC. Solidation treatment of adult acute lymphoblastic leukemia: a perspective randomized trial comparing allogenic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995; 86: 1619-1626.
3. Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningham I, Castro Malaspinia H, O'Reilly RJ, Keever CA. Antileukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990; 75: 2250-2262.
4. Trinchieri G. Biology of natural killer cells. Adv Immunol 1985; 47: 187-376.
5. Fao R, Fierro MT, Cesano A, Guarini A, Bonferroni M, Raspadori D, Miniero R, Lauria F, Gavosto F. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease. Blood 1991; 78: 1041-1046.
6. Panayotides P, Porwit A, Sydgren AM, Wasserman J, Reizenstein P. Resistance of some leukemic blasts to lysis by lymphokine activated (LAK) cells. Eur J Haematol 1988; 40: 362-367.
7. Storkus WJ, Dawson J. Target structures involved in natural killing (NK): characteristics, distribution, and candidate molecules. Crit Rev Immunol 1991; 10: 393-416.
8. Patarroyo M, Priet J, Rincon J, Timonen T, Lundberg C, Lindbom I, Asjo B, Gahmberg CG. Leukocyte-cell adhesion: a molecular process fundamental in leukocyte physiology. Immunol Rev 1990; 114: 67-108.
9. Ritz J, Schmidt RE, Michon J, Hercend T, Schlossman SF. Characterization of functional surface structures on human natural killer cells. Adv Immunol 1988; 42: 181-211.
10. Schmidt RE, Bartley G, Levine H, Schlossman SF, Ritz J. Functional characterization of LFA-1 antigen in the interaction of human NK clones and target cells. J Immunol 1985; 135: 1020-1025.
11. Shaw S, Ginther Luce GE, Quinones R, Gress RE, Springer TA, Sanders MA. Two antigen-independent adhesion pathways used by human cytotoxic T-cell clones. Nature 1986; 323: 262-264.
12. Schmits R, Kundig TM, Baker DM, Shumaker G, Simard JJL, Duncan G, Wakeham A, Shahinian A, van der Heiden A, Bachmann MF, Ohashi PS, Mak TW, Hickstein DD. LFA-1 deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. J Exp Med 1996; 183: 1415-1426.
13. Gong J, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994; 8: 652-658.